The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease
|ClinicalTrials.gov Identifier: NCT01615003|
Recruitment Status : Unknown
Verified January 2014 by Guang'anmen Hospital of China Academy of Chinese Medical Sciences.
Recruitment status was: Recruiting
First Posted : June 8, 2012
Last Update Posted : January 14, 2014
|Condition or disease||Intervention/treatment||Phase|
|Coronary Heart Disease Unstable Angina Blood Stasis Syndrome||Drug: Xuesaitong soft capsule Drug: Xuesaitong soft capsule Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Analysis of Blood Stasis Syndromeand of Coronary Heart Disease Related MicroRNA Genomics and Target Gene Regulatory Networks|
|Study Start Date :||May 2012|
|Estimated Primary Completion Date :||July 2014|
|Estimated Study Completion Date :||December 2014|
Experimental: Xuesaitong soft capsule group
Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
Drug: Xuesaitong soft capsule
Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
Placebo Comparator: control group
Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
Drug: Xuesaitong soft capsule Placebo
Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
- the change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina [ Time Frame: 1 month ]The change of Cycle threshold of relational microRNA in coronary artery disease with unstable angina by real RT-PCR.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01615003
|Contact: Fei Teng, email@example.com|
|Guang'an men Hispital||Recruiting|
|Beijing, Beijing, China, 100000|
|Contact: Fei Teng, master 13581985462 firstname.lastname@example.org|
|Contact: Gui Yu, master 13488835663|
|Principal Investigator: Jie Wang, doctor|